Molecular classification of enteroviruses not identified by neutralization tests. (Research).

We isolated six viruses from patients diagnosed with aseptic meningitis or hand, foot, and mouth disease. The cytopathic effect of these viruses on cultured cells was like that of enteroviruses. However, viral neutralization tests against standard antisera were negative. Phylogenetic analysis with the complete VP4 nucleotide sequences of these 6 viruses and 29 serotypes of enteroviruses classified 3 of the viruses as serotype echovirus type 18 (EV18) and 3 as serotype human enterovirus 71 (HEV71). These results were confirmed by remicroneutralization tests with HEV-monospecific antisera or an additional phylogenetic analysis with the complete VP4 nucleotide sequences. Phylogenetic analysis with complete VP4 genes is more useful than neutralization tests with enterovirus serotype-specific antisera in identifying enterovirus serotypes.

**********

The human enterovirus (HEV) genus of the family Picor-naviridae includes the human pathogens that cause a wide spectrum of acute disease, including hand, foot, and mouth disease (1), aseptic meningitis (2,3), encephalitis (3-6), and neonatal sepsislike disease (7,8). Sixty-four serotypes of HEV have been recognized antigenically by neutralization tests with anti-HEV antibodies (9). HEVs have long been classified on the basis of serotype-specific antisera in virus neutralization tests (1, 10), the only method available for serotyping HEVs. However, virus neutralization is both labor- and time-intensive, and antigenic variants in many serotypes of HEV can affect test results (1).

The HEV genome comprises a 5' nontranslated region (NTR), a long open reading frame that encodes a protein of approximately 2,100 amino acid residues, a short 3' NTR, and a polyadenylated tail. The polyprotein is co- and post-translationally cleaved to yield four structural proteins: VP4, VP2, VP3, and VP1 (1). Recently, attempts have been made to classify the HEV serotypes by using the partial nucleotide sequences of the HEV genomes (i.e., the 5' NTR [11-13], the VP4-VP2 junction [14-16], and VP1 [17-20]). Methods for molecular classification of HEVs should not only identify the serotypes rapidly but also detect antigenic variant strains or new serotypes. A new serotype of HEV has recently been identified by comparing the complete VP1 nucleotide sequences; its proposed name is HEV73 (19).

To investigate the HEV serotypes of six HEV-like viruses that were not neutralized by standard HEV typing sera, we determined the complete VP4 nucleotide sequences of these 6 viruses and 21 HEV antigenically defined serotypes, then performed phylogenetic analysis with another 8 HEV serotypes available from GenBank. The classifications of the untypeable viruses were confirmed by using HEV-monospecific antisera or an additional phylogenetic analysis with the VP4 sequences. The molecular classification of HEV with the complete VP4 sequences is useful for identifying the HEV serotypes.

Methods

Virus Isolation and the Neutralization Test

The clinical specimens were injected into Vero, RD-18S, or MA104 cells to isolate viruses. All cells were grown in minimum essential medium (MEM) containing 10% fetal bovine serum (FBS) and maintained in MEM containing 1% to 2% FBS after being added to 48-well plates (Sumitomo Bakelite, Tokyo, Japan). The cells were incubated for 1 week, after which culture fluids were passaged and incubated for another week. Cultured cells showing cytopathic effects were regarded as virus isolation-positive and, together with the culture supernatant, were harvested and stored at -80 [degrees] C before use. To serotype the viruses, microneutralization tests were performed with antiserum pools of Lim and Benyesh-Melnick (21) (Denka Seiken, Tokyo, Japan) or in-house monospecific immune sera against coxsackie virus Al0 (CAV10), CAV16, and HEV71, respectively.

Viruses

Of the six viruses that could not be identified by the neutralization tests described above (Table 1), strains OC/0071, OC/0073, and OC/00272 were isolated from patients diagnosed with aseptic meningitis by using RD-18S cells. OC/00219, OC/00260, and OC/00261 were isolated from patients diagnosed with hand, foot, and mouth disease or aseptic meningitis by using Vero cells. No sera from these patients was available for analysis. Twenty-one serotypes were isolated and identified in our laboratory during 1995-2000 (Table 2); these strains were used in the experiments. For additional investigations of HEV71, we used eight HEV71 strains isolated and identified in our laboratory (Table 3).

RNA Extraction and Reverse Transcription

Viral RNAs were extracted from the cell-culture supernatants by using ISOGEN-LS (Nippon Gene, Tokyo, Japan). cDNAs were synthesized with an Omniscript Reverse Transcriptase Kit (QIAGEN K.K., Tokyo, Japan) according to the manufacturer's instructions. The primers used for the synthesis were EVP-2 (5'-CCTCCGGCCCCTGAATGCGGCTAAT-3' relative to nt 444-468 in the genome of Poliovirus (PV) Sabin 1 strain) (22) and OL68-1 (5'-GGTAAYTTCCACCACCANCC-3' relative to nt 1178-1197 of Sabin 1), as described (23).

Polymerase Chain Reaction Amplification of cDNAs

Polymerase chain reaction (PCR) was performed by using 2 [micro]L of each cDNA in a 50-[micro]L reaction mixture containing 1.5 U of Taq DNA polymerase (Takara Shuzo, Shiga, Japan), 20 pmol of EVP-2 primer, and 20 pmol of OL68-1 primer. Each reaction was incubated in a GeneAmp 9700 thermal cycler (Applied Biosystems, Foster City, CA) according to the following protocol: 5 minutes at 95 [degrees] C, 40 cycles of 95 [degrees] C for 30 seconds, 68 [degrees] C for 30 seconds, 72 [degrees] C for 1 minute, and then at 72 [degrees] C for 5 minutes. After the appearance of approximately 750 bp-specific amplified fragments was confirmed by agarose gel electrophoresis, the amplicons were purified with a QIAquick PCR purification kit (QIAGEN).

DNA Sequence Analysis

Approximately 100 ng of purified amplicon was used in the reaction with the BigDye Terminator Cycle Sequencing FS Ready Reaction Kit (Applied Biosystems), and DNA sequencing was performed by using an ABI PRISM 310 DNA sequencer (Applied Biosystems). All DNA sequencings were performed on both strands using EVP-4 (5'-CTACTTTGGGTGTCCGTGTT-3' relative to nt 541-560 in the genome of PV Sabin 1 strain) as the forward primer and OL68-1 as the reverse primer (23). Sequencer software (version 3.0; Hitachi Software, Tokyo, Japan) was used to determine the approximately 600-bp nucleotide sequence spanning 5' NTR to one third of VP2 (including all of VP4), translate nucleotide sequence to amino acid sequence, and decide the complete VP4 coding sequence of each virus.

Phylogenetic Analysis

A phylogenetic tree based on the complete VP4 nucleotide sequence was constructed by the neighbor-joining method (24) as implemented with the CLUSTAL X program (version 1.63b, December 1997; http://www-igbmc.u-strasbg.fr/BioInfo/ClustalX/). The reliability of the neighbor-joining tree was estimated by bootstrap analysis with 1,000 pseudoreplicate datasets. The complete VP4 sequences of eight HEV serotypes not isolated in our laboratory were obtained from GenBank and included in the HEV analysis. Complete VP4 nucleotide sequences of another 18 HEV71 strains were obtained from GenBank and used in the phylogenetic analysis.

Remicroneutralization Tests

According to results of HEV phylogenetic analysis with the complete VP4 nucleotide sequences, remicroneutralization tests using monospecific antiserum against echovirus 18 (EV18; Denka Seiken), or HEV71 (anti-HEV71/BrCr and anti-HEV71/C7 sera; both supplied by the National Institute of Infectious Diseases, Japan) were performed to confirm the serotype of the untypeable strains from the first microneutralization assay.

Complete VP1 Nucleotide Compared with Deduced Amino Acid Sequences of HEV71 Strains

The complete VP1 nucleotide sequences of HEV71 strains OC/00168, 0C/00219, OC/00260, and OC/00261 were determined by the same procedure described above, except for the primers. The primers used for the analysis of VP1 nucleotide sequence were 71 F2399 (5'-AGAAYTTYACCATGAAACTG-3' relative to nt 2380-2399 in the genome of HEV71 MS/7423/ 87 strain [25]; the nucleotide positions of the following are also relative to this strain: 71F2793 (5'-AGACATAACTGGYTACGCCAC-3' nt 2774-2793) and 71F3042 (5'-CATGTCACCYGCGAGCGCTT-3' nt 3023-3042) as the forward, 71R2712 (5'-CTACCAARCCTGCCCTACTG-3' nt 2693-2712), 71R3066 (5'-GGTACCCGTCGTAAAACCAC-3' nt 3047-3066) and 71R3376 (5'-AAGTTGCCCACGTAGATGGC-3' nt 3357-3376) as the reverse. The VP1 nucleotide sequence of HEV71 BrCr strain (25) was obtained from GenBank. Sequencer software (version 3.0; Hitachi Software) was used for determination and comparison of the complete VP1 nucleotide and deduced amino acid sequences of these HEV71 strains.

Results

Determination of Complete VP4 Nucleotide Sequences of HEVs

During May to July 2000, six viruses isolated in our laboratory (OC/0071, OC/0073, OC/00219, OC/00260, OC/00261, and OC/00272) could not be neutralized by standard pools of HEV typing sera and three antimonospecific sera (Table 1). However, the cytopathic effects of these viruses on RD-18S or Vero cells were all HEV-like (data not shown). To identify the serotypes of these untypeable HEV-like viruses by a method other than the neutralization assay, we determined the complete VP4 nucleotide sequences of all 6 strains and another 21 HEV serotypes identified in our laboratory over the past 6 years. The 3' end of the VP4 gene of each virus was determined from the deduced amino acid sequences as described (26,27). The complete VP4 nucleotide sequences of all HEV strains used in this study were 207 nt long, and the deduced amino acid sequences of all VP4 proteins were 69 amino acids long (data not shown).

Phylogenetic Analysis of HEVs

A phylogenetic tree was constructed based on the complete VP4 nucleotide sequences of the 6 HEV-like untypeable strains, the 21 HEV serotypes identified in our laboratory as prototype strains, and another 8 HEV serotypes available from the GenBank database (Figure 1). The 29 different HEV serotypes defined antigenically were clustered in four distinct lineages, as described (23). Three of the six untypeable strains (OC/0071, OC/0073, and OC/00272) were classified nearest to EV 18. The VP4 nucleotide sequences of strains OC/0071 and OC/0073 were identical. The VP4 gene sequence of OC/00272 was the same as that of OC/99-Hanasaka, which was used as a prototype strain for EV18. The nucleotide sequences of these two clusters differed by 5 nt, but the deduced amino acid sequences were the same (data not shown). The other three untypeable strains (OC/00219, OC/00260, and OC/00261) were classified nearest to HEV71. The VP4 sequence of OC/ 00219 was the same as that of OC/00168, which was used as a prototype strain for HEV71. The VP4 nucleotide sequences of OC/00260 and OC/00261 were identical. The difference between these two clusters was 11 nt. The deduced amino acid sequences were the same (data not shown).

[FIGURE 1 OMITTED]

Remicroneutralization Tests

According to the results of the phylogenetic analysis based on the complete VP4 nucleotide sequences, remicroneutralization tests were performed. Microneutralization tests using the monospecific immune serum for EV18 were done against OC/ 0071, OC/0073, and OC/00272, and this serum neutralized these viruses. The same tests, using the two species of monospecific immune serum, anti-HEV71/BrCr and anti-HEV71/ C7, were performed against OC/00219, OC/00260, and OC/ 00261, but neither serum neutralized the viruses (Table 4).

Phylogenetic Analysis of HEV71 Strains

To establish whether OC/00219, OC/00260, and OC/ 00261 belong to HEV71, we used another phylogenetic analysis based on the complete VP4 nucleotide sequences of various HEV71 strains (Figure 2). In this analysis, we examined eight HEV71 strains isolated and identified in our laboratory from 1996 to 2000 (Table 3). All these HEV71 strains except for OC/9632 were identified by microneutralization tests with anti HEV71/BrCr serum (data not shown). Of the HEV71 strains available from GenBank, two were isolated in the United States in 1970 and 1987, respectively (25), four in Malaysia in 1997 (15), one in Singapore in 1998 (28), eight in Taiwan in 1998 (15,28), two in the United Kingdom in 1999, and one in China (year unknown). The HEV71 strains were clustered in three distinct genotypes, designated A, B, and C. The genotype nomenclature of HEV71 strains for phylogenetic analyses based on the VP1 (17,25,28) and VP4 (29) nucleotide sequences has been reported, and the results (Figure 2) were consistent with previous findings. Among the HEV71 strains that were identified in our laboratory, only OC/99-Ikeda was classified in genotype C. Seven of eight strains identified in our laboratory by neutralization tests were classified in genotype B; five of these had the same VP4 nucleotide sequence. OC/00219, OC/00260, and OC/00261 were also classified in this genotype. This result demonstrated that strains OC/00219, OC/00260, and OC/00261 were HEV71 serotypes.

[FIGURE 2 OMITTED]

Comparison of the Complete VP1 Nucleotide and Deduced Amino Acid Sequences of HEV71 Strains

Strains OC/00219, OC/00260, and OC/00261 were classified in HEV71 by the phylogenetic analysis, although these viruses were not neutralized by monospecific anti-HEV71 sera. Because the VP1 protein contains a number of important neutralization sites (1,30), we determined the complete VP1 nucleotide sequences and compared the deduced amino acid sequences of OC/00219, OC/00260, and OC/00261. OC/ 00168 used as a prototype strain for HEV71 was also analyzed because this strain was neutralized by anti-HEV71/BrCr serum; moreover, its VP4 gene was the same as that of OC/ 00219 (Figure 2). The complete VP1 nucleotide sequences of these strains were 891 nt long, and the deduced amino acid sequences were 297 amino acids long. The differences of VP1 nucleotide sequences were 4 to 42 nt (0.4% to 4.7%), and the difference of deduced amino acid sequences was one amino acid (0.3%) among these viruses. The differences of VP1 nucleotide sequences between OC/00168 and OC/00219 were 4 nt (0.4%), and the deduced VP1 amino acid sequences of these strains were the same. The VP1 nucleotide and deduced amino acid sequences of OC/00260 and OC/00261 were identical (data not shown). The deduced VP1 amino acid sequences of these four strains were compared with that of BrCr (Table 5). There were 18 amino acid (6%) differences between BrCr and other strains. The different amino acid positions of strains OC/00168, OC/00219, OC/00260, and OC/ 00261 against BrCr were the same. Any mutated residues distinguishable BrCr and OC/00168 from OC/00219, OC/00260, and OC/00261 were not recognized in the VP1 amino acid sequences.

Discussion

The serotype identification of HEVs has been performed by microneutralization tests using standard HEV antiserum pools (1,10). Since >60 serotypes of HEV are known to infect humans (1,19), the HEV serotype is almost impossible to identify by using monospecific antiserum from the first microneutralization test. Furthermore, the neutralization test is labor-intensive and time-consuming, requiring several weeks. As an alternative, identification based on nucleotide sequences has been used successfully in several laboratories (15,19,20, 23,29,31-35). To investigate the serotypes of the six untypeable HEV-like viruses that were not neutralized by the standard HEV antisera, we used phylogenetic analyses based on the complete VP4 nucleotide sequences of HEVs and were able to determine the serotype of each virus in the light of these results. OC/0071, OC/0073, and OC/00272 were thought to be EV18 strains by the phylogenetic analysis (Figure 1) and were neutralized by the monospecific anti-EV 18 serum. These results indicate that the phylogenetic analysis based on the VP4 nucleotide sequence is consistent with the result of the microneutralization tests using the serotype-specific sera. OC/ 00219, OC/00260, and OC/00261 were thought to be HEV71 strains by the same analysis (Figure 1), but these viruses were not neutralized by the two monospecific anti-HEV71 sera. The phylogenetic analysis based on the HEV71 VP4 sequences confirmed that these viruses were HEV71 strains belonging to genotype B (Figure 2). We considered that OC/00219, OC/ 00260, and OC/00261 were all HEV71 strains not neutralized by anti-HEV71/BrCr and anti-HEV71/C7 sera, both available as standard monospecific anti HEV71 serum in Japan. These results also indicate that phylogenetic analysis with the VP4 sequences of HEVs can identify the serotypes in the same way as neutralization tests with HEV serotype-specific antisera. We are now preparing antiimmune sera against OC/00219, OC/ 00260, and OC/00261, respectively, to confirm antigenically that these are the prime strains of HEV71 neutralized by anti-HEV71/BrCr serum.

Oberste et al. have shown that HEV VP1 nucleotide sequences correlate with antigenically defined serotypes and have demonstrated the utility of VP1 sequences as a molecular surrogate for antigenic type (19,35). They have also shown that the VP1 sequences have a better correlation with HEV serotypes than the 5' NTR or the VP4-VP2 junction (36). The phylogenetic analysis based on the VP4 sequences we have described also correlates well with HEV serotypings by antiimmune sera. We used 21 HEV serotypes antigenically defined in our laboratory and another 8 strains available from GenBank as prototype strains in this analysis. We do not know whether 29 serotypes are sufficient for the phylogenetic analysis of HEV, as there are >60 serotypes. The good result of HEV phylogenetic classification based on the VP4 sequences might depend on the prototype numbers (29 of 64 serotypes) that we used. Ishiko et al., who performed HEV phylogenetic analyses based on VP4 sequences (23), used 45 HEV serotypes as prototype strains and obtained a phylogenetic tree similar to ours (Figure 1) except for a difference in the prototype strain numbers. Another phylogenetic analysis based on the VP4 sequences in this article was performed against the HEV71 strains (Figure 2). For this analysis, the HEV71 strains were clustered in three distinct genotypes, and the nomenclature was almost the same as for the HEV71 analyses based on the VP1 nucleotide sequences (17,25). Recently, Chu et al. also reported the appropriateness of the phylogenetic analysis with the VP4 sequences for the molecular epidemiology of HEV71 outbreak in Taiwan in 1998 (29). These results suggest that the phylogenetic analysis based on the VP4 nucleotide sequences is also useful as a molecular surrogate for antigenic HEV serotyping. The analysis was more convenient based on the VP4 sequences than the VP1 sequences, since the complete VP4 sequence is 207 nt and the complete VP1 sequences are 834 to 951 nt (35), although the 3' third of the VP1 sequence of 365 nt was used (32).

The VP4 nucleotide sequences of OC/99-Hanasaka and OC/00272 were identical, but the results of neutralization assays were different. OC/99-Hanasaka was easily neutralized by HEV pooled sera against EV18, but OC/00272 was not. The same results were observed for strains OC/00168 and OC/ 00219 HEV71, i.e., the results of their neutralization tests differed in spite of the VP4 sequence identity. These results indicate that the VP4 nucleotide sequences are highly conserved even though the neutralizable epitopes are antigenic variants. We compared the VP4 nucleotide and deduced amino acid differences of HEV71 strains, BrCr (25), E1387 (15), OC/9632, OC/99-Ikeda, OC/0078, OC/00219, and OC/00260. HEV71 genotypes indicated 1 to 37 nt (0.5% to 17.9%) differences. However, we found no amino acid differences (100% identity) (Table 6). Complete homology of the HEV71 VP4-deduced amino acid sequences has also been described (20,29), and Singh et al. demonstrated amino acid substitutions in the VP2 and VP3 regions, with the greatest variation in VP1 (20). These results indicate that VP4 is the most stable protein; accordingly, VP4 genes will be suitable for the molecular identification of HEV serotypes in the future.

VP4 is not exposed on the outer surface of the capsid, and no neutralizable epitopes appear to exist in VP4. On the other hand, VP1, VP2, and VP3 are outer capsid proteins and contain neutralizable epitopes (37,38). A number of important neutralization epitopes may exist on VP1 (1,30,39). To confirm the important neutralization sites on VP1, we compared the deduced VP1 amino acid sequences of HEV71 strains OC/ 00168, OC/00219, OC/00260, and OC/00261. OC/00168 was neutralized by anti-HEV71/BrCr serum, while OC/00219, OC/ 00260, and OC/00261 were not. Comparison of the deduced VP1 amino acid sequences showed that no mutated residues on the VP1 region corresponded to the result of the neutralization tests. This result indicates that either the important neutralization epiotopes for anti-HEV71/BrCr serum do not exist on the VP1 protein, or the epitopes are specifically masked in the cases of OC/00219, OC/00260, and OC/00261. Further analysis against the VP2 and VP3 regions of these strains should allow interpretation of these findings.

Table 1. Unidentified enterovirus strains and patient information,
Osaka, Japan, 2000

           Patient age               Date of    Clinical   Isolated
Strain       (years)     Specimen   sampling    symptoms    cells

OC/0071        2          Stool     5/11/2000     AM (a)    RD-18S
OC/0073        2 (b)       CSF      5/11/2000     AM        RD-18S

OC/00219       0          Throat    7/7/2000      HFMD       Vero
                           swab

OC/00260       0          Throat    7/18/2000    HFMD,       Vero
                           swab                   AM

OC/00261       0 (c)      Stool     7/18/2000    HFMD,       Vero
                                                  AM

OC/00272       6          Stool     7/18/2000     AM        RD-18S

(a) AM = aseptic meningitis; CSF = cerebrospinal
fluid; HFMD = hand, foot, and mouth disease.

(b) Same patient as OC/0071.

(c) Same patient as OC/00260.
Table 2. Characteristics of 21 human enterovirus (HEV) serotypes
antigenically defined, Osaka, Japan, 1995-2000

HEV                    Age                  Date of    Isolated
serotype   Strain    (years)   Specimen     sampling    cells

PV1       OC/00417      0     Throat swab  10/13/2000    Vero
PV2       OC/00138      0        Stool      6/10/2000    Vero
PV3       OC/99355      0     Nasal mucus  11/8/1999     Vero
EV3       OC/00467      7        Stool     11/13/2000   RD-18S
EV6       OC/99350      0        Stool     11/8/1999    RD-18S
EV7       OC/96221      7     Throat swab  7/22/1996    MA104
EV9       OC/00129      3       CSF (a)     6/8/2000    RD-18S
EV11      OC/98535      3        Stool     9/23/1998    RD-18S
EV16      OC/95378      1     Throat swab  9/11/1995    MA104
EV18       OC/99-       7        Stool     11/8/1999    RD-18S
          Hanasaka
EV25      OC/00263      0        Stool     7/17/2000    RD-18S
EV30      OC/97633      1        Stool     9/29/1997    RD-18S
CAV9      OC/96234      4         CSF       8/2/1996    RD-18S
CAV16     OC/00351     NA     Throat swab  8/31/2000     Vero
CBV1      OC/00364      0         CSF       9/6/2000     Vero
CBV2      OC/99284      0        Stool     9/11/1999    RD-18S
CBV3      OC/97620      6         CSF      9/19/1997    RD-18S
CBV4      OC/00362      1        Stool      9/8/2000     Vero
CBV5      OC/00223      0     Throat swab   7/7/2000     Vero
CBV6      OC/00325      0         CSF       8/8/2000     Vero
HEV71     OC/00168      2     Throat swab  6/21/2000     Vero

(a) CSF = Cerebrospinal fluid; NA = not available.
Table 3. Characteristics of eight human enterovirus 71
strains, as antigenically defined, Osaka, Japan, 1996-2000

              Age                   Date of     Clinical    Isolated
Strain       (years)   Specimen    sampling     symptoms     cells

OC/9632       NA (a)     Stool     4/11/1996      HFMD       MA104
OC/99-Ikeda    6         Stool     9/11/1999    HFMD, AM      Vero
OC/0078        1      Throat swab  5/18/2000    HFMD, AM      Vero
OC/0080       NA         Stool     5/9/2000     Diarrhea      Vero
OC/0096        5          CSF      5/25/2000  Diarrhea, AM    Vero
OC/00114       0          CSF      5/31/2000     Fever        Vero
OC/00125       6      Throat swab  6/7/2000   Encephalitis    Vero
OC/00168       4      Throat swab  6/21/2000   Herpangina     Vero

(a) NA = Not available; HFMD = Hand, foot, and mouth
disease; AM = aseptic meningitis; CSF = cerebrospinal fluid.
Table 4. Results of re-microneutralization tests with human
enterovirus (HEV) monospecific antiserum, Osaka, Japan, 2000

                                      HEV monospecific antiserum

                       Predicted              Anti-
           Isolated       HEV         Anti-   HEV71/    Anti-
Strain      cells     Serotype (a)    EV18     BrCr    HEV71/C7

OC/0071     RD-18S      EV18 (b)       +        ND        ND
OC/0073     RD-18S       EV18          +        ND        ND
OC/00219     Vero        HEV71         ND       --        --
OC/00260     Vero        HEV71         ND       --        --
OC/00261     Vero        HEV71         ND       --        --
OC/00272    RD-18S       EV18          +        ND        ND

(a) Serotypes were predicted from the
phylogenetic analysis in Figure 1.

(b) EV18 = echovirus 18; ND = Test not done.
Table 5. Differences in deduced VP1 amino acid sequences (aa
1-297) of human enterovirus 71 strains BrCr, OC/00168, OC/00219,
OC/00260, and OC/00261

                                    Strain
Amino acid
position     BrCr (a)   OC/00168   OC/00219   OC/00260   OC/00261

18             Lys        Arg        Arg        Arg        Arg
22             Pro        Gln        Gln        Gln        Gln
30             Pro        Gln        Gln        Gln        Gln
31             Asp        Asn        Asn        Asn        Asn
43             Lys        Glu        Glu        Glu        Glu
58             Ala        Thr        Thr        Thr        Thr
98             Lys        Glu        Glu        Glu        Glu
145            Arg        Glu        Glu        Glu        Glu
164            Asp        Glu        Glu        Glu        Glu
167            Asp        Glu        Glu        Glu        Glu
172            Pro        Gln        Gln        Gln        Gln
183            Ser        Leu        Leu        Leu        Leu
184            Ser        Thr        Thr        Thr        Thr
244            Glu        Lys        Lys        Lys        Lys
246            Ser        Pro        Pro        Pro        Pro
249            Ile        Val        Val        Val        Val
275            Ser        Ala        Ala        Ala        Ala
282            Asp        Asn        Asn        Ser        Ser

(a) VP1 nucleotide sequence was obtained from GenBank (accession
no. U22521) and translated into the deduced amino acid sequence.
Table 6. Number of nucleotide and deduced amino acid differences
between the VP4 genes of human enterovirus 71 strains. (a)

                       OC/   OC/    OC/    OC/   OC/99-
          BrCr  E1387  9632  0078  00219  00260  Ikeda

BrCr             33     37    36    37     32      34
E1387      0            10     7     8      7      33
OC/9632    0      0           13    14     15      37
OC/0078    0      0      0           1     10      37
OC/00219   0      0      0     0           11      36
OC/00260   0      0      0     0     0             34
OC/99-
 Ikeda     0      0      0     0     0      0

Acknowledgments

We thank K. Haruki and T. Murakami for helpful suggestions and K. Takino and S. Minoshiro for technical assistance.

References

(1.) Melnick JL. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Fields BN, Knipe DM, Howley PM, Channock RM, Melnick JL, Monath TP, et al., editors. Fields virology, 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1996. p.655-712.

(2.) Berlin LE, Rorabaugh ML, Heldrich F, Roberts K, Doran T, Modlin JF. Aseptic meningitis in infants <2 years of age: diagnosis and etiology. J Infect Dis 1993;168:888-92.

(3.) Rotbart HA. Meningitis and encephalitis. In: Rotabart HA, editor. Human enterovirus infections. Washington: ASM Press; 1995. p.271-89.

(4.) Bello M. Viral meningoencephalitis caused by enterovirus in Cuba from 1990-1995. Rev Argent Microbiol 1997;29:176-83.

(5.) Chang L-Y, Huang Y-C, Lin Z-Y. Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease. Lancet 1998;352:367-8.

(6.) Lum LCS, Wong KT, Lam SK, Chua KB, Goh AY, Lim WL, et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr 1998;133: 795-8.

(7.) Chambon M, Delage C, Bailly J-L, Gaulme J, Dechelotte P, Henquell C, et al. Fatal hepatic necrosis in a neonate with echovirus 20 infection: use of the polymerase chain reaction to detect enterovirus in liver tissue. Clin Infect Dis 1997;24:523-4.

(8.) Modlin JF. Update on enterovirus infections in infants and children. Adv Pediatr Infect Dis 1997;12:155-80.

(9.) Mayo MA, Pringle CR. Virus taxonomy-1997. J Gen Virol 1998;79:649-57.

(10.) Minor PD, Brown F, Domingo E, Hoey E, King A, Knowles N, et al. The Picornaviridae. In: Murphy FA, Fauquet CM, Bishop DHL, Ghabrial SA, Jarvis AW, Martelli GP, et al., editors. Virus taxonomy. Sixth report of the International Committee on Taxonomy of Viruses. New York: Springer-Verlag; 1995. p.268-74.

(11.) Bailly J-L, Borman AM, Peigue-Lafeuille H, Kean KM. Natural isolates of echovirus type 25 with extensive variations in IRES sequences and different translational efficiencies. Virology 1996;215:83-96.

(12.) Diedrich S, Driesel G, Schreier E. Sequence comparison of echovirus type 30 isolates to other enteroviruses in the 5' noncoding region. J Med Virol 1995;46:148-52.

(13.) Kopecka H, Brown B, Pallansch M. Genotypic variation in coxsackie B5 isolates from three different outbreaks in the United States. Virus Res 1995;38:125-36.

(14.) Huttunen P, Santii J, Pulli T, Hiyypia T. The major echovirus group is genetically coherent and related to coxsackie B viruses. J Gen Virol 1996;77:715-25.

(15.) Shimizu H, Utama A, Yoshii K, Yoshida H, Yoneyama T, Sinniah M, et al. Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997-1998. Jpn J Infect Dis 1999;52:12-5.

(16.) Pulli T, Koskimies P, Hyypia T. Molecular comparison of coxsackie A virus serotypes. Virology 1995;211:30-8.

(17.) Brown BA, Oberste MS, Alexander JR JP, Kennett ML, Pallansch MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 1999;73:9969-75.

(18.) Oberste MS, Maher K, Flemister MR, Marchetti G, Kilpatrick DR, Pallansch MA. Comparison of classic and molecular approaches for the identification of untypeable enteroviruses. J Clin Microbiol 2000;38:1170-4.

(19.) Oberste MS, Schnurr D, Maher K, al-Busaidy S, Pallansch MA. Molecular identification of new picornaviruses and characterization of a proposed enterovirus 73 serotype. J Gen Virol 2001;82:409-16.

(20). Singh S, Chow VTK, Chan KP, Ling AE, Poh CL. RT-PCR, nucleotide, amino acid and phylogenetic analyses of enterovirus type 71 strains from Asia. J Virol Methods 2000;88:193-204.

(21). Lim KA, Benyesh-Melnick M. Typing of viruses by combination of antiserum pools. Application to typing of enteroviruses (coxsackie and ECHO). J Immunol 1960;84:309-17.

(22.) Nomoto A, Omata T, Toyoda H, Kuge S, Horie H, Kataoka Y, et al. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci U S A 1982;79:5793-7.

(23.) Ishiko H, Shimada Y, Yonaha M, Sakae K. Phylogenetic analysis and rapid diagnosis of enteroviruses. [in Japanese] Clin Virol 1999;27:283-93.

(24.) Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;4:406-25.

(25.) Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 1995;39:195-205.

(26.) Arnold E, Luo M, Vriend G, Rossmann MG, Palmenberg AC, Parks GD, et al. Implications of the picornavirus capsid structure for polyprotein processing. Proc Natl Acad Sci U S A 1987;84:21-5.

(27.) Lee W-M, Monroe SS, Rueckert RR. Role of maturation cleavage in infectivity of picornaviruses: activation of an infectosome. J Virol 1993;67:2110-22.

(28.) Shih S-R, Ho M-S, Lin K-H, Wu S-L, Chen Y-T, Wu C-N, et al. Genetic analysis of enterovirus 71 isolated from fatal and non-fatal cases of hand, foot and mouth disease during an epidemic in Taiwan, 1998. Virus Res 2000;68:127-36.

(29.) Chu P-Y, Lin K-H, Hwang K-P, Chou L-C, Wang C-F, Shih S-R, et al. Molecular epidemiology of enterovirus 71 in Taiwan. Arch Virol 2001;146:589-600.

(30.) Minor PD. Antigenic structure of picornaviruses. Curr Top Microbiol Immunol 1990;161:121-54.

(31.) Arola A, Santti J, Ruuskanen O, Halonen P, Hyypia T. Identification of enteroviruses in clinical specimens by competitive PCR followed by genetic typing using sequence analysis. J Clin Microbiol 1996;34:313-8.

(32.) Caro V, Guillot S, Delpeyroux F, Crainic R. Molecular strategy for `serotyping' of human enteroviruses. J Gen Virol 2001;82:79-91.

(33.) Drebot MA, Nguan CY, Campbell JJ, Lee SHS, Forward KR. Molecular epidemiology of enterovirus outbreaks in Canada during 1991-1992: identification of echovirus 30 and coxsackievirus B 1 strains by amplicon sequencing. J Med Virol 1994;44:340-7.

(34.) Kim GR, Lee JS, Jung YT, Chung YJ, Rhyu MG. Nucleotide sequencing of a part of the 5'-noncoding region of echovirus type 9 and rapid detection during the acute phase of aseptic meningitis. Arch Virol 1997;142:853-60.

(35.) Oberste MS, Maher K, Kilpatrick DR, Pallansch MA. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol 1999;73:1941-8.

(36.) Oberste MS, Maher K, Kilpatrick DR, Flemister MR, Brown BA, Pallansch MA. Typing of human enteroviruses by partial sequencing of VP1. J Clin Microbiol 1999;37:1288-93.

(37.) Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 [Angstrom] resolution. Science 1985;229:1358-65.

(38.) Rossman MG, Arnold A, Erickson JW, Frankenberger EA, Griffith JP, Hecht H-J, et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature (London) 1985;317:145-53.

(39.) Mateu MG. Antibody recognition of picornaviruses and escape from neutralization: a structural view. Virus Res 1995;38:1-24.

Dr. Kubo is a research scientist at Osaka City Institute of Public Health and Environmental Sciences. His research interests include molecular biology and molecular epidemiology of respiratory infectious diseases.

Address for correspondence: Hideyuki Kubo, Department of Microbiology, Osaka City Institute of Public Health and Environmental Sciences, 8-34 Tojocho, Tennoji-ku, Osaka 543-0026, Japan; fax: [phone]; e-mail: [e-mail]

Hideyuki Kubo, * Nobuhiro Iritani, * and Yoshiyuki Seto *

* Osaka City Institute of Public Health and Environmental Sciences, Osaka, Japan